Author

M. Liddell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:DNA methylation· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

F. Xu· 2 shared J. Li· 2 shared K. Li· 2 shared L. Chang· 2 shared L. Tulum· 2 shared P. Kukic· 2 shared P. Xu· 2 shared Q. Zhang· 2 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

F. Xu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The phosphoproteome is a first responder in tiered cellular adaptation to chemical stress followed by proteomics and transcriptomics alteration

P. Chen, Y. Li, F. Xu, Z. Zhang, T. Zuo, J. Guo, K. Li, S. Liu, S. Li, J. Yin, L. Chang, P. Kukic, M. Liddell, L. Tulum, P. Carmichael, , P. Xu

This study compares transcriptomics, proteomics, and phosphoproteomics responses in HepG2 and AC16 cells to chemical exposure, finding phosphoproteomics changes occur earlier and at lower concentrations than transcriptomics.

Chemosphere · Dec 1, 2023Peer-reviewedPharmacology & Toxicology

Using NAMs to characterize chemical bioactivity at the transcriptomic, proteomic and phosphoproteomic levels

Y. Li, Z. zhang, S. Jiang, F. Xu, L. Tulum, K. Li, S. Liu, S. Li, L. Chang, M. Liddell, F. Tu, X. Gu, P. L. Carmichael, A. White, S. Peng, , P. Xu

This paper integrates multi-omic data to characterize chemical bioactivity at transcriptomic, proteomic, and phosphoproteomic levels, showing how early phosphoproteomic changes drive downstream effects.

bioRxiv · May 18, 2022 · PreprintPharmacology & Toxicology